Citing MDx Reimbursement Changes, NeoGenomics Reports Flat Q2 Revenues | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer genetics diagnostic company NeoGenomics today reported flat revenues for the second quarter, as changes to Medicare's reimbursement for molecular diagnostics negatively impacted operations.

The Fort Myers, Fla.-based company said that revenues for the three months ended June 30 totaled $15.6 million, the same as a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.